AR102803A1 - Vacunas de reovirus aviar - Google Patents

Vacunas de reovirus aviar

Info

Publication number
AR102803A1
AR102803A1 ARP150100252A ARP150100252A AR102803A1 AR 102803 A1 AR102803 A1 AR 102803A1 AR P150100252 A ARP150100252 A AR P150100252A AR P150100252 A ARP150100252 A AR P150100252A AR 102803 A1 AR102803 A1 AR 102803A1
Authority
AR
Argentina
Prior art keywords
sequence identity
seq
sequence
identity
avian reovirus
Prior art date
Application number
ARP150100252A
Other languages
English (en)
Inventor
S Sellers Holly
Original Assignee
The Univ Of Georgia Res Found Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Univ Of Georgia Res Found Inc filed Critical The Univ Of Georgia Res Found Inc
Publication of AR102803A1 publication Critical patent/AR102803A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12261—Methods of inactivation or attenuation
    • C12N2720/12264—Methods of inactivation or attenuation by serial passage
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/14—Reoviridae, e.g. rotavirus, bluetongue virus, Colorado tick fever virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)

Abstract

Reivindicación 1: Un reovirus aviar aislado, en donde el reovirus aviar comprende: (a) una proteína sigma C que comprende una secuencia de aminoácidos con al menos aproximadamente 80% de identidad de secuencia, al menos aproximadamente 85% de identidad de secuencia, al menos aproximadamente 90% de identidad de secuencia, al menos aproximadamente 95% de identidad de secuencia, al menos aproximadamente 96% de identidad de secuencia, al menos aproximadamente 97% de identidad de secuencia, al menos aproximadamente 98% de identidad de secuencia o al menos aproximadamente 99% de identidad de secuencia con la SEQ ID Nº 2 y/o SEQ ID Nº 4; (b) un gen S1 que comprende una secuencia de nucleótidos con al menos aproximadamente 80% de identidad de secuencia, al menos aproximadamente 85% de identidad de secuencia, al menos aproximadamente 90% de identidad de secuencia, al menos aproximadamente 95% de identidad de secuencia, al menos aproximadamente 96% de identidad de secuencia, al menos aproximadamente 97% de identidad de secuencia, al menos aproximadamente 98% de identidad de secuencia o al menos aproximadamente 99% de identidad de secuencia con la SEQ ID Nº 1 y/o SEQ ID Nº 3; (c) una proteína sigma C que comprende una secuencia de aminoácidos con al menos aproximadamente 85% de identidad de secuencia, al menos aproximadamente 90% de identidad de secuencia, al menos aproximadamente 95% de identidad de secuencia, al menos aproximadamente 96% de identidad de secuencia, al menos aproximadamente 97% de identidad de secuencia, al menos aproximadamente 98% de identidad de secuencia o al menos aproximadamente 99% de identidad de secuencia con la SEQ ID Nº 6; o (d) un gen S1 que comprende una secuencia de nucleótidos con al menos aproximadamente 85% de identidad de secuencia, al menos aproximadamente 90% de identidad de secuencia, al menos aproximadamente 95% de identidad de secuencia, al menos aproximadamente 96% de identidad de secuencia, al menos aproximadamente 97% de identidad de secuencia, al menos aproximadamente 98% de identidad de secuencia o al menos aproximadamente 99% de identidad de secuencia con la SEQ ID Nº 5. Reivindicación 19: Una composición inmunológica para aumentar anticuerpos en aves de corral comprendiendo la composición un reovirus aviar de cualquiera de las reivindicaciones 1 a 16. Reivindicación 27: Un método para prevenir la artritis viral y/o tenosinovitis en un ave del orden Galliformes, comprendiendo el método administrar al ave un reovirus aviar aislado de cualquiera de las reivindicaciones 1 a 16 o una composición o vacuna de cualquiera de las reivindicaciones 17 a 21. Reivindicación 39: Un método para detectar un reovirus aviar en una muestra, comprendiendo el método producir un producto de amplificación de reacción en cadena de polimerasa (PCR) con al menos un cebador derivado de la SEQ ID Nº 1, SEQ ID Nº 3 o SEQ ID Nº 5.
ARP150100252A 2014-01-29 2015-01-29 Vacunas de reovirus aviar AR102803A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461932995P 2014-01-29 2014-01-29

Publications (1)

Publication Number Publication Date
AR102803A1 true AR102803A1 (es) 2017-03-29

Family

ID=53757708

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150100252A AR102803A1 (es) 2014-01-29 2015-01-29 Vacunas de reovirus aviar

Country Status (11)

Country Link
US (3) US9968671B2 (es)
EP (1) EP3099789A4 (es)
JP (1) JP6682441B2 (es)
KR (2) KR102340265B1 (es)
CN (1) CN106232808A (es)
AR (1) AR102803A1 (es)
BR (1) BR112016017333A2 (es)
CL (2) CL2016001906A1 (es)
MX (1) MX2016009747A (es)
RU (2) RU2724497C2 (es)
WO (1) WO2015116778A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6682441B2 (ja) 2014-01-29 2020-04-15 ユニバーシティ オブ ジョージア リサーチ ファンデーション，インコーポレーテッド トリレオウイルスワクチン
MX2022006546A (es) * 2019-12-02 2022-07-01 Univ Georgia Reovirus aviar atenuado cepas 94826 c140 y 96139 c140.
CN110760485B (zh) * 2019-12-09 2023-02-24 天津渤海农牧产业联合研究院有限公司 一株禽呼肠孤病毒毒株及应用
CN114592088B (zh) * 2022-02-16 2024-04-02 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 一种用于检测或区分禽呼肠孤病毒4种不同基因型的多重pcr试剂盒及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999024582A1 (en) * 1997-11-07 1999-05-20 Dalhousie University Novel reovirus-derived proteins, nucleic acids encoding same, and uses therefor
ATE292674T1 (de) * 1999-01-29 2005-04-15 Akzo Nobel Nv Neue antigenklasse von geflügelreoviren
WO2008076518A2 (en) * 2006-10-25 2008-06-26 University Of Georgia Research Foundation, Inc. Reovirus compositions and methods of use
WO2009093251A2 (en) * 2008-01-24 2009-07-30 Gavish-Galilee Bio Applications Ltd Reovirus vaccine based on sigma c protein sequence
JP6682441B2 (ja) 2014-01-29 2020-04-15 ユニバーシティ オブ ジョージア リサーチ ファンデーション，インコーポレーテッド トリレオウイルスワクチン

Also Published As

Publication number Publication date
MX2016009747A (es) 2016-11-09
US20180236061A1 (en) 2018-08-23
BR112016017333A2 (pt) 2017-10-17
CL2021003044A1 (es) 2022-08-26
WO2015116778A1 (en) 2015-08-06
KR20160113137A (ko) 2016-09-28
RU2708316C2 (ru) 2019-12-05
RU2019137459A3 (es) 2020-04-27
EP3099789A1 (en) 2016-12-07
KR102340265B1 (ko) 2021-12-15
RU2016134909A3 (es) 2019-02-18
EP3099789A4 (en) 2017-09-13
KR20210022165A (ko) 2021-03-02
RU2016134909A (ru) 2018-03-02
US9968671B2 (en) 2018-05-15
US10588958B2 (en) 2020-03-17
US11090377B2 (en) 2021-08-17
US20170028055A1 (en) 2017-02-02
JP2017506503A (ja) 2017-03-09
CN106232808A (zh) 2016-12-14
RU2724497C2 (ru) 2020-06-23
CL2016001906A1 (es) 2017-02-17
RU2019137459A (ru) 2019-12-20
JP6682441B2 (ja) 2020-04-15
US20200069788A1 (en) 2020-03-05

Similar Documents

Publication Publication Date Title
BR112018013930A2 (pt) vírus oncolítico, vírus que expressa três genes heterólogos, composição farmacêutica, vírus para o uso, produto de fabricação, método de tratamento de câncer e uso do vírus
PH12018500855A1 (en) Herpes simplex virus vaccine
BR112016019267A2 (pt) métodos e composições para perfil de dna
ES2721309T3 (es) Composición para preparar tagatosa y método para preparar tagatosa a partir de fructosa
AR102803A1 (es) Vacunas de reovirus aviar
BR112018067536A2 (pt) sistema de transpóson e métodos de uso
AR105822A1 (es) Análogos de insulina
AR087885A1 (es) Enzimas utiles para la industria alimenticia
CO2017001614A2 (es) Vacuna en vector recombinante de adenovirus aviar serotipo 9
MX2018014163A (es) Composiciones de nucleotido marcados y metodos para el secuenciamiento de acido nucleico.
MX2015016765A (es) Celulas aviares para la produccion mejorada de virus.
WO2015150492A3 (en) An isolated donor mhc-derived peptide and uses thereof
AR118857A1 (es) Microorganismo que produce l-aminoácido y método de producción de l-aminoácido usando el mismo
RU2016152662A (ru) Микроорганизм рода Escherichia, продуцирующий L-триптофан, и способ продуцирования L-триптофана с использованием данного микроорганизма
BR112018003580A2 (pt) molécula de ácido nucléico, método para apresentar um polipeptídeo alvo, proteína recombinante, partícula do tipo viral, composição farmacêutica, polipeptídeo, vetor, célula hospedeira e método para preparar a proteína recombinante
AR083445A1 (es) siARN CONTRA LA FIBROSIS
AR110626A1 (es) Paramixovirus y sus usos
AR102762A1 (es) Secuencia de oligonucleótidos para uso en ingeniería de rutas metabólicas
AR105291A1 (es) Métodos y conjuntos de elementos para la detección del oídio
WO2015106067A3 (en) Lucigen yellow (lucy), a yellow fluorescent protein
AR102333A1 (es) Selectividad eficiente de proteínas recombinadas
CL2019000405A1 (es) Vacunas virales.
EP3546594A3 (en) Multi-copy reference assay
ES2671745T3 (es) Detección de Neisseria gonorrhoeae
AR109167A1 (es) Aumento de la fertilidad en especies bovinas